In the News
Press Releases
Alzheon to Present ALZ-801 (Valiltramiprosate) Oral Tablet Program Update as Potential Treatment for Alzheimer’s Disease in Adults with Down Syndrome at 4th International Trisomy 21 Research Conference
New Results Position ALZ-801 to Potentially Become the First Oral Agent that Can Slow or Even Stop and Prevent Alzheimer’s Pathology in Patients and Healthy Individuals at Risk for the Disease
Alzheon Announces Closing of Oversubscribed $50 Million Series D Financing Round to Accelerate Completion of APOLLOE4 Phase 3 Trial and Expansion of Product Portfolio
Proceeds Will Accelerate Both Completion of APOLLOE4 Phase 3 Study Evaluating Oral Tablet ALZ-801 (Valiltramiprosate) and Regulatory Filings for Patients with Early Alzheimer’s Disease
Alzheon Appoints Susan Flint as Vice President of Clinical Operations, Patrick Kesslak, PhD, as Vice President of Clinical Development & Medical Affairs, and Erwan de Naurois as Vice President of Finance
New Executives Will Support Completion of APOLLOE4 Phase 3 Trial Evaluating Oral Tablet ALZ-801 (Valiltramiprosate) and Expansion of Product Portfolio
Alzheon to Present ALZ-801 (Valiltramiprosate) Phase 3 Program Update and Industry-Leading Disease Modifying Effects from Phase 2 Trial in Patients with Early Alzheimer’s Disease at AD/PD and NDDS Scientific Conferences
New Results Position ALZ-801 Tablet to Potentially Become the First Oral Agent that Can Slow or Even Stop and Prevent Alzheimer’s Pathology in Patients and Healthy [...]
Alzheon Reports Industry-Leading Disease Modifying Effects from Phase 2 Biomarker Trial of Oral Tablet ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease
29% Reduction in Plasma P-tau181, Core Biomarker of Alzheimer’s Pathology, Observed after 6 Months Treatment in Carriers of One or Two Copies of APOE4 Gene who Represent Two Thirds of Patients with Disease
Alzheon to Present at H.C. Wainwright Bioconnect Conference on January 10, 2022
Alzheon CEO Dr. Martin Tolar Will Provide Overview of Company Business and Update on Oral Anti-Amyloid ALZ-801 Phase 3 Program in Alzheimer’s Disease